Unparalleled Expertise
in Gene Therapy and
Phagocyte Disorders
Founded in 2019, we are a spin-out of the University of Zurich (UZH), built on decades of world-leading research in gene therapy and phagocyte-driven diseases. Our founding team brings together unparalleled scientific and clinical expertise, enabling us to rapidly translate transformative discoveries into real-world impact.
Our Mission
CURING AT THE SOURCE
Our mission is bold in ambition and clear in focus: to cure genetic diseases by correcting them at their source –within the DNA. Through our cutting-edge gene therapy platform, we aim to deliver life-changing, one-time treatments for patients affected by phagocyte-driven immune and neurodegenerative disorders.
By uniting scientific precision with a deep commitment to patient impact, we are redefining what’s possible –transforming once-incurable conditions into treatable, curable realities.
Our Board
Proven Leadership, Strategic Vision
Our Board brings together a track record of success in building and scaling innovative biotech companies, with deep domain knowledge in gene therapy, rare diseases, and venture-backed growth. Their strategic guidance and sector insight ensure we stay focused, capital-efficient, and globally competitive.
01
Innovation
At Somagenetix, we push the boundaries of science to discover and implement groundbreaking therapies.
02
Precision
We believe that effective treatments require precise solutions, and our technologies are designed to target genetic diseases at their core.
03
Compassion
Our patients are at the heart of everything we do. We are committed to improving lives with care and empathy.
04
Integrity
We maintain the highest ethical standards in our research, clinical trials, and partnerships, ensuring that every step of our process is transparent and trustworthy.
05
Collaboration
Our success is built on teamwork, both within our company and with our external partners, advisors, and patients.
What Drives Us
Our Team
Built to Deliver
We’ve brought together a highly focused, execution-driven team of industry veterans with deep expertise across the entire gene therapy value chain – including preclinical development, clinical strategy, regulatory pathways, manufacturing, and commercialization. Our core team is supported by a trusted network of expert advisors and consultants, allowing us to remain agile while scaling with precision.